Prr Reblozyl™
luspatercept for injection

Patient Identification	Prescriber Details
Name:	Name:
	Signature:
	Date:

Prescriber's Checklist for Women of Childbearing Potential

Prior to Initiation of Treatment

Treatment with REBLOZYL should not be started if the woman is pregnant or in women of childbearing potential not using an effective method of contraception.

- The use of REBLOZYL is not recommended in pregnancy and in women of childbearing potential not using effective contraception.
- There are no data from the use of REBLOZYL in pregnant women. Studies in animals have shown reproductive toxicity and embryo-foetal toxicity. Clinical implications are potential foetal loss and teratogenicity.

☐ Provide counselling before treatment initiation regarding the potential teratogenic risk of REBLOZYL and required actions that may help to minimize this risk.

☐ Inform women of childbearing potential of the necessity for an effective method of contraception while on treatment and for 3 months after discontinuation.

☐ A pregnancy test is recommended in women of childbearing potential before starting treatment.

☐ Provide the Patient Card to women of childbearing potential.

Duration of Treatment

☐ Provide regular counselling regarding the potential teratogenic risk of REBLOZYL and required actions that may help to minimize this risk.

☐ Remind women of childbearing potential that they must use an effective method of contraception during treatment with REBLOZYL.

During treatment with REBLOZYL, women must not become pregnant. If a woman becomes pregnant or wants to become pregnant, she should be informed of the potential for hazard to the fetus.

Discontinuation of Treatment

☐ Counsel women of childbearing potential that an effective method of contraception should be maintained for at least 3 months following discontinuation of treatment with REBLOZYL.

☐ Provide counselling in the event of pregnancy and evaluation of the outcome of any pregnancy.

☐ Not applicable (this patient did not become pregnant while on treatment or within 3 months of discontinuation of REBLOZYL)

Should a pregnancy occur during treatment or within 3 months following discontinuation of treatment with REBLOZYL, remind the patient that it should be reported to the prescriber.

Celgene Inc. encourages healthcare professionals and patients to report any pregnancy and any suspected adverse reactions. This will allow quick identification of new safety information. More information regarding how to report side effects can be found in the Canadian Product Monograph: https://www.bms.com/assets/bms/ca/documents/productmonograph/REBLOZYL_EN_PM.pdf. For more information or to obtain a copy of this document, please contact medical information by calling 1-866-463-6267.

CLEAR FORM

Bristol Myers Squibb™

Date of internal approval: December 2020
2007CA2000447E